Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: BuySellSignals Research
$5.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd Receives USFDA Approval For Quinapril Tablets


Tuesday, 30 Apr 2013 03:42am EDT 

Aurobindo Pharma Ltd announced that the Company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and Quinapril Tablets USP 5mg, 10mg, 20mg and 40mg (ANDA 202725). Quinapril Tablets USP 5mg, 10mg, 20mg and 40mg is the generic equivalent of Pfizer Pharmaceuticals Ltd’s Accupril Tablets 5mg, 10mg, 20mg and 40mg respectively, indicated for the treatment of hypertension and falls under the Cardiovascular (CVS) therapeutic category. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India 

Company Quote

723.65
3.75 +0.52%
6:28am EDT